๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced Unresectable Hepatocellular Carcinoma

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC NCT07500220Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200Phase 31 site๐Ÿ“ Guangzhou Second Affiliated Hospital of Guangzhou Medical University ยท Tests: Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE Observational Study Protocol: LIVER-R NCT06252753n/a160 sites๐Ÿ“ Birmingham๐Ÿ“ Mobile๐Ÿ“ Phoenix AstraZeneca ยท Tests: Durvalumab-based combination therapies in observational study setting, Durvalumab-based combination therapies in observโ€ฆ A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma NCT07478302Phase 12 sites๐Ÿ“ Fuzhou๐Ÿ“ Nanning Suzhou Suncadia Biopharmaceuticals Co., Ltd. ยท Tests: SHR-2524 Injection, Bevacizumab Injection Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations NCT06915753Phase 116 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Stanford Tyra Biosciences, Inc ยท Tests: TYRA-430 Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors NCT07523529Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05985798Phase 31 site๐Ÿ“ Guangzhou Second Affiliated Hospital of Guangzhou Medical University ยท Tests: Sin-Bev-TACE, Len-TACE Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma NCT07560488Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Bevacizumab Biosimilar IBI305, ipilimumab N01, Sintilimab, HAIC Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) NCT07293468Phase 2, Phase 31 site๐Ÿ“ Hong Kong Tuen Mun Hospital ยท Tests: Transarterial chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), SIRT Yttrium-90, Atezolizumab &โ€ฆ A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma NCT05440708Phase 1, Phase 221 sites๐Ÿ“ Birmingham๐Ÿ“ La Jolla๐Ÿ“ Los Angeles Tvardi Therapeutics, Incorporated ยท Tests: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression NCT07327034Phase 251 sites๐Ÿ“ Hefei๐Ÿ“ Hefei๐Ÿ“ Hefei Abbisko Therapeutics Co, Ltd ยท Tests: ABSK-011+BSC, Placebo+BSC Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors NCT05176483Phase 1122 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Palo Alto Exelixis ยท Tests: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC NCT06742424Phase 21 site๐Ÿ“ Chengdu West China Hospital ยท Tests: PD-L1 antibody, Bevacizumab, HAIC-FOLFOX CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma NCT05257590Phase 25 sites๐Ÿ“ Kaohsiung City๐Ÿ“ Keelung๐Ÿ“ Tainan TaiRx, Inc. ยท Tests: Nivolumab Injection [Opdivo], CVM-1118 Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy NCT07493668Phase 21 site๐Ÿ“ Seongnam-si CHA University ยท Tests: Fostrox, Lenvatinib A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer NCT06764316Phase 136 sites๐Ÿ“ Dothan๐Ÿ“ Duarte๐Ÿ“ Orlando Bayer ยท Tests: BAY 3547926, BAY 3547922, BAY 3713391, BAY 3713389 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site๐Ÿ“ Jacksonville Mayo Clinic ยท Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. NCT07227012Phase 1, Phase 260 sites๐Ÿ“ Irvine๐Ÿ“ Irvine๐Ÿ“ Irvine Pfizer ยท Tests: PF-08634404, Ipilimumab Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598Phase 212 sites๐Ÿ“ Beverly Hills๐Ÿ“ La Jolla๐Ÿ“ Miami Replimune, Inc. ยท Tests: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma NCT06737913Phase 23 sites๐Ÿ“ Lanzhou๐Ÿ“ Guangzhou๐Ÿ“ Zhengzhou Sun Yat-sen University ยท Tests: HAI Adebrelimab, intravenous infusion (IV) of Adebrelimab (ADE), intravenous infusion (IV) of Bevacizumab (Bev.), HAIC โ€ฆ Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer NCT05168163Phase 216 sites๐Ÿ“ Scottsdale๐Ÿ“ Jacksonville๐Ÿ“ Weston Academic and Community Cancer Research United ยท Tests: Atezolizumab, Cabozantinib, Lenvatinib Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors NCT05269381Phase 1, Phase 21 site๐Ÿ“ Jacksonville Mayo Clinic ยท Tests: Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection Peg IFNฮฑ-2b Therapy for Unresectable Mid to Late Stage HBV-HCC NCT07769827NA1 site๐Ÿ“ Nanjing Jinling Hospital, China ยท Tests: Combined Peg IFNฮฑ-2b treatment group Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma NCT07793695Phase 21 site๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targetโ€ฆ Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC NCT06397222Phase 21 site๐Ÿ“ Guangzhou Second Affiliated Hospital of Guangzhou Medical University ยท Tests: Sin-Bev-SIRT Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma NCT05317819Phase 311 sites๐Ÿ“ Changhua๐Ÿ“ Chiayi City๐Ÿ“ Chiayi City Polaris Group ยท Tests: ADI-PEG20, Placebo A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma NCT07010497Phase 23 sites๐Ÿ“ Seoul๐Ÿ“ Seoul๐Ÿ“ Seoul Asan Medical Center ยท Tests: irpagratinib Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma NCT07099274Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. NCT07607769n/a24 sites๐Ÿ“ Ancona๐Ÿ“ Ancona๐Ÿ“ Bergamo AstraZeneca ยท Tests: STRIDE A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC NCT07547553Phase 1, Phase 221 sites๐Ÿ“ Bengbu๐Ÿ“ Hefei๐Ÿ“ Hefei Huahui Health ยท Tests: Will receive HH-009 injection 20 mg/kg, Q3W, Will receive HH-009 injection 30 mg/kg, Q3W
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy